Objectives. To determine how sensitively SSc-associated ANAs are detected by a standard identification algorithm compared with an extensive panel of ANA identification assays, and to assess the distribution of SSc-associated ANAs and SSc organ system involvement in patients without skin involvement (limited SSc).
Introduction
SSc is a rare CTD characterized by widespread fibrosis and vasculopathy, which can affect the skin and several internal organs [1] . Patients with an established disease are classified according to the extent of skin thickening as lcSSc or dcSSc [2] . Subjects without skin involvement were included as a third subset, besides lcSSc and dcSSc, in the classification criteria according to LeRoy and Medsger for early SSc [3] . This group was called limited SSc (lSSc) and defined by the presence of an RP and a SSc-type nailfold capillary pattern or/and SSc-associated ANA [3] . A large prospective study has validated LeRoy and Medsger's criteria [4] . Recently, this last group (lSSc) has gained interest since ANA detection has, besides its diagnostic value, also prognostic value, as specific ANAs are associated with particular disease manifestations [5] . Examples are the association between anti-topo I and lung fibrosis and anti-RNA polymerase III and scleroderma renal crisis [57] . Nowadays, in most clinical autoimmune laboratories, the detection of SSc-associated ANAs is limited to ACAs and anti-topo I, whereby a typical standard identification algorithm consists of ANA detection with IIF followed by ANA identification with specific immunoassays, such as ELISA or line immunoassay (LIA). However, other specific ANAs, like anti-RNA polymerase III, anti-fibrillarin, anti-PM/Scl and anti-Th/To, have also been associated with SSc, yet are not picked up by most standard ANA identification algorithms. Importantly, the detection of these ANAs allows classifying a patient with RP as lSSc. In this study, we used an extended approach for ANA identification, including IIF, LIA, western blotting (WB), protein radio-immunoprecipitation and RNA immunoprecipitation. Our objectives were to determine the gain of performing an extended battery of ANA identification techniques vs a standard algorithm (IIF and LIA) for the detection of SSc-associated ANA and to assess the distribution of specific ANA and SSc organ system involvement in SSc patients without skin involvement (lSSc).
Patients and methods

Patients
One hundred and forty-five consecutive patients presenting to the Scleroderma Clinic of Ghent University Hospital and fulfilling the LeRoy and Medsger criteria for early SSc were studied [3, 8] . Based on the extension of skin involvement, patients were divided into lSSc (no skin involvement), lcSSc (skin involvement distal to the elbows, knees and clavicles) and dcSSc (skin involvement proximal to the elbows, knees and clavicles) [2, 3] . Nailfold videocapillaroscopy to assess the presence of SScassociated nailfold capillary patterns was performed as described previously [8, 9] . ANAs were detected and identified by an extensive panel of assays, as described below. This study was conducted after approval by the Ethics Committee of the Ghent University Hospital and all patients signed informed consent.
Definition of SSc organ system involvement SSc organ system involvement was evaluated at baseline based on the disease severity scale by Medsger, with some modifications [10] . All patients were assessed by the same investigator (V.S.). For description of SSc organ system involvement, the scores of each category were dichotomized. Peripheral vascular involvement was recorded if pitting scars, digital tip ulcerations or digital gangrene were present (at least Stage 2 on disease severity scale). Joint/tendon involvement was recorded if finger-to-palm distance in flexion was >1.9 cm (at least Stage 2 on disease severity scale). Muscle involvement was recorded if proximal weakness found on physical examination (at least Stage 1 on disease severity scale) was accompanied by creatin kinase elevation. Gastrointestinal (GI) tract involvement was recorded if malabsorption, distal oesophageal hypoperistalsis, abnormal small bowel series, bacterial overgrowth or pseudoobstruction were present (at least Stage 1 on disease severity scale). Lung involvement was recorded if vital capacity or diffusing capacity of the lung for carbon monoxide (DL CO ) was <80% of predicted, pulmonary fibrosis was seen on radiography or tricuspid regurgitation gradient was >36 mmHg (at least Stage 1 on disease severity scale). Heart involvement was recorded if ECG arrhythmia, chronic heart failure or left ventricular ejection fraction <45% were present (at least Stage 2 on disease severity scale). Kidney involvement was recorded if there was a history of scleroderma renal crisis (at least Stage 1 on disease severity scale).
ANA detection
IIF on HEp-2000 cells was performed according to the manufacturer's instructions (Immunoconcepts, Sacramento, CA, USA). Since IIF was used as a sensitive screening method, a serum dilution of 1 : 40 was used in order to obtain optimal sensitivity.
LIA
The INNO-LIA ANA Update (Innogenetics NV, Zwijnaarde, Belgium) was performed as described previously [11] . This assay contains the following recombinant or natural antigens: SmB, SmD, RNP-A, RNP-C, RNP-70k, Ro52/ SSA, Ro60/SSA, SSB, Cenp-B, Topo-I/Scl-70, Jo-1, ribosomal P and histones. Each line of the test strip was compared with the respective line on a reference strip, obtained by testing a cut-off control sample in each run.
WB with a nuclear extract K562 cells were cultured in RPMI supplemented with 10% fetal calf serum, 200 mM L-glutamine and 100 U/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). Twenty million cells were washed three times with PBS, resuspended in 5 ml buffer A [10 mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (pH 7.9), 10 mM KCl, 1.5 mM MgCl 2 and 0.5 mM dithiothreitol (DTT)] and incubated for 5 min on ice. Following homogenization by 10 strokes with a Teflon pestle, nuclei were pelleted (500 g 5 min), resuspended in 3 ml S1 (0.25 M sucrose, 10 mM MgCl 2 ) and layered over 3 ml S2 solution (0.35 M sucrose, 0.5 mM MgCl 2 ). After the centrifugation (2500 g, 10 min), the pellet was resuspended in Laemmli sample buffer (2% SDS, 10% glycerol, 50 mM TrisHCl pH 6.8) with freshly added b-mercaptoethanol (5%) and boiled for 5 min. The proteins were quantified with 2D Quant (GE Healthcare, Uppsala, Sweden) according to the manufacturer's protocol and stored at À20 C.
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Prior to one-dimensional SDSPAGE, the proteins were boiled for 5 min with fresh b-mercaptoethanol. Two hundred and forty micrograms were loaded on a 10% TrisHCl polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA, USA) and electrophoresis was performed by applying 150 V for 30 min, followed by 200 V for 1 h. Subsequently, WB of the gel was performed on nitrocellulose membranes (Bio-Rad Laboratories) in 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS) (pH 11) for 3 h at 50 V. The electrophoretic transfer of proteins was checked by Ponceau S staining. The blot was blocked in 5% non-fat dry milk (Bio-Rad Laboratories) in PBS for 1 h and cut in small lanes. Each lane was incubated overnight with serum (1/100 dilution in 5% milk/PBS). The lanes were washed three times with 0.3% Tween-20/PBS and incubated with horseradish peroxidase (HRP)-labelled goat anti-human immunoglobulin (Ig)G for 1 h (1/50 000 in 0.3% Tween-20 in PBS). Electrochemiluminescence detection was carried out by means of Supersignal West Dura Extended Duration Substrate (Pierce, Rockford, IL, USA) in the Versadoc Imaging System (Bio-Rad Laboratories). By means of landmarks placed on the blot, the different lanes were matched with each other and with a molecular weight marker. Figure 1a shows the results of the positive control samples.
Protein radio-immunoprecipitation with a total cell extract Protein radio-immunoprecipitation was performed as described previously, with slight modifications [12] . One hundred million K562 cells were cultured overnight in 100 ml methionine-and cystine-deficient RPMI ( Beads were washed four times in IP buffer and resuspended in 380 ml IP buffer before the addition of 120 ml labelled K562 cell extract. Samples were rotated for 2 h at 4 C. Beads were washed three times in IP buffer followed by tris-buffered saline (TBS) buffer [10 mM TrisHCl (pH 7.4), 150 mM NaCl] before being resuspended in 50 ml Laemmli sample buffer, supplemented with fresh b-mercaptoethanol (5%). After heating (95 C,
FIG. 1 Results of positive control sera used for WB (a) and protein radio-immunoprecipitation (b). (a)
WB of a nuclear cell extract was incubated with normal human serum (healthy) and serum from patients with SSc. Reactivity against topo I (Scl70) is seen at 100 and 70 kDa, against SSA/Ro60 at 60 kDa, against SSA/Ro52 and SSB at, respectively, 52 and 48 kDa, against U1RNP at 70 kDa (70 k), 33 kDa (A), 28 kDa (B/B 0 ), 23 kDa (C) and 16 kDa (D), against PM/Scl at 100 kDa, against centromere protein A, B and C at, respectively, 17, 80 and 140 kDa, and against fibrillarin at 34 kDa [23] . (b) Autoradiograph of a 10% SDSPAGE after protein radio-immunoprecipitation with a total cell extract. Faint aspecific reactivity is seen with normal human serum (healthy), as reported previously [24] . Reactivity against topo I (Scl70) is seen at 100 kDa, against SSA/Ro60 and SSB at, respectively, 60 and 48 kDa, against RNA polymerase I and III at respectively 120 and 190 kDa and 138 and 155 kDa, against U1RNP at 33 kDa (A), 28 kDa (B/B 0 ) and 23 kDa (C), against PM/Scl at 100 kDa, against Ku at 70 and 80 kDa and against fibrillarin at 34 kDa [23, 25, 26] . fixed (in methanol : water : glacial acetic acid (4.5 : 4.5 : 1), enhanced in Amplify Fluorographic Reagent (GE Healthcare) and dried using a Bio-Rad Laboratories gel dryer at 60 C for 3 h. Labelled proteins were visualized by autoradiography. Figure 1b shows the results of the positive control samples.
RNA immunoprecipitation with a total cell extract RNA immunoprecipiation was performed on the ANApositive samples, in which other ANA identification techniques did not yield a specific ANA reactivity, and on all samples with a nucleolar fluorescence pattern. RNA immunoprecipitation was performed as described previously [12] . Briefly, 10 ml of patient sera was mixed with 2 mg of protein A-sepharose beads in 500 ml of IP buffer and incubated with end-over-end rotation for 2 h at 4 C. The IgG-coated sepharose was washed four times in 500 ml of IP buffer and was resuspended in 400 ml of NET-2 buffer [50 mM TrisHCl (pH 7.5), 150 mM NaCl, 0.05% Nonidet P-40]. This suspension was incubated with 100 ml of a total HeLa cell extract, derived from 6 Â 10 6 cells, on the rotator for 2 h at 4 C. The antigenbound sepharose beads were then collected by centrifugation, washed four times with NET-2 buffer and resuspended in 300 ml of NET-2 buffer. To extract bound RNAs, 30 ml of 3.0 M sodium acetate, 30 ml of 10% SDS and 300 ml of phenol/chloroform/isoamyl alcohol (50 : 50 : 1, containing 0.1% 8-hydroxyquinoline) were added to the sepharose beads. After agitation in a vortex mixer and spinning for 1 min, RNAs were recovered in the aqueous phase after ethanol precipitation and dissolved in 20 ml of electrophoresis sample buffer composed of 10 M urea, 0.025% bromophenol blue and 0.025% xylene cyanol-FF in Tris-Borate-EDTA (TBE) buffer [90 mM TrisHCl (pH 8.6), 90 mM boric acid and 1 mM EDTA]. The RNA samples were denatured at 65 C for 5 min and loaded on 7 M urea10% polyacrylamide gels. Electrophoresis was performed by applying 400 V. Subsequently, the gels were silver-stained (Bio-Rad Laboratories).
Statistical analysis
All analyses were performed with PASW 18.0 (Chicago, IL, USA). For all categorical data analyses, Fisher's exact tests were used.
Results
Sensitivity of ANA identification techniques for SSc-associated ANAs
One hundred and forty-five consecutive SSc patients were included in this study. Seventy-seven per cent were female and the mean (S.D.) age was 54 (13) years. The mean (S.D.) duration of RP was 10 (12) years. One hundred and forty-four patients were Caucasians, whereas one was from North-African origin. The demographic and clinical characteristics of the patients with and without skin involvement can be found in Table 1 . The definitions used for defining ANA specificities were based on positivity by at least one detection technique (presented in Table 2 ). Table 2 shows the sensitivity of the proposed standard ANA identification algorithm (IIF and LIA) and the combination of this algorithm with all other techniques for the detection of SSc-associated ANAs. The standard algorithm found at least one ANA from the list mentioned in Table 2 in 74% (n = 107) of all serum samples, whereas the combination of all identification techniques resulted in a sensitivity of 88% (n = 127). The ANA reactivities that were not picked up by the standard algorithm were anti-RNA polymerase III (n = 11), anti-PM/Scl (n = 4), Th/ To (n = 3) and anti-Ku (n = 1). Additionally, the combination of all identification techniques had a higher sensitivity for some ANAs (Table 3 ). Looking at the relative contribution of different non-standard techniques, we found that the addition of protein radio-immunoprecipitation to the standard algorithm resulted in a substantial increase of the sensitivity for identification of at least one ANA in a serum sample (86%, n = 125), whereas the addition of WB had a smaller benefit (79%, n = 114) (see supplementary table 1, available as supplementary data at Rheumatology Online). RNA immunoprecipitation was the only technique that could identify anti-Th/To. Prevalence of specific ANAs and SSc organ system involvement in patients with lSSc Table 4 shows the prevalence of the different ANAs in patients with and without skin involvement (lSSc). Compared to patients with skin involvement (lcSSc and dcSSc), ACA and anti-Th/To were seen more frequently in patients with lSSc, whereas anti-topo I and anti-RNA polymerase III were found less frequently. We explored the SSc organ involvement in patients with lSSc based on a modification of the Medsger severity scale (Table 1) . Twenty-six patients (63%) had involvement of at least one organ system: 22 had lung involvement, 1 muscle involvement, 1 heart involvement, 1 GI tract involvement and 1 peripheral vascular involvement. Among the 22 patients with lung disease, 15 had ACA, 2 anti-Th/To and 1 anti-topo I antibodies.
TABLE 1 Demographic and clinical characteristics of patients with and without skin involvement
Discussion
The presence of ANAs is one of the hallmark features of SSc. Anti-topo I, ACA, anti-fibrillarin, anti-PM/Scl and anti-RNA polymerase I and III are part of the LeRoy and Medsger classification criteria for SSc [3] . Besides these ANAs, anti-Th/To and anti-U1RNP have also been associated with disease manifestations of SSc in several studies [5, 6, 13, 14] . In this study, we identified specific ANAs in a monocentric consecutive cohort of SSc patients by means of several ANA detection platforms, including LIA, WB, protein radio-immunoprecipitation and RNA immunoprecipitation, in order to determine the sensitivity of a standard ANA identification algorithm for SSc-associated ANAs. In addition, we focussed on the serological profile and clinical manifestations of patients without skin involvement (lSSc). In most clinical autoimmune laboratories, cascade testing is used to identify ANAs, whereby IIF screening precedes specific second-line identification assays. For this study, we opted for the use of the INNO-LIA ANA Update as second-line test, as it was thoroughly validated and optimized in multiple studies [1517] . We compared the performance of this standard ANA identification algorithm (IIF and LIA) with the ANA reactivities picked up by a combination of this algorithm and several laborious non-standard ANA identification techniques, which are mostly confined to a research setting. The overall sensitivity for identification of at least one ANA in a serum sample by means of the standard algorithm was 74%, which increased to 88% when the results of all ANA identification techniques were combined. Our results indicate that a substantial increase of the sensitivity can be obtained when immunoassays that detect anti-RNA polymerase III, anti-PM/Scl and anti-Th/To are added to a standard ANA identification algorithm. Although commercially available immunoassays exist for some of these ANA reactivities, validation studies have shown discordant results with the conventional identification techniques, as applied in this study. For example, anti-RNA 21 (15) 22 ( polymerase III antibody ELISA showed suboptimal specificity compared with protein radio-immunoprecipitation [18, 19] , whereas anti-PM/Scl-75 and anti-PM/Scl-100 antibodies detected by LIA were linked to other disease manifestations than in studies employing double immunodiffusion [5, 20] . Concerning the gain of performing different non-standard techniques, a major increase was obtained by adding protein radio-immunoprecipitation to the routine algorithm, whereas adding WB had only limited benefit. It must be noted that the frequencies of specific ANAs in a SSc cohort are dependent on the classification criteria used to include patients, as well as immunogenetic and ethnic factors. For example, anti-fibrillarin antibodies have been associated with the Black race, probably explaining the lack of anti-fibrillarin positive patients in our Caucasian cohort [5, 21] .
One innovative feature of this study is the inclusion of consecutive patients with lSSc, according to LeRoy and Medsger [3] . This cross-sectional study is the first to describe the distribution of specific ANAs and clinical manifestations in this subset. Our results demonstrate that this subset mainly harbours ACA, anti-SSA and anti-Th/To antibodies. Specific ANAs included in the LeRoy and Medsger criteria were present in 73% of the patients with lSSc, underlining the role of ANA detection in the identification of this subset. Compared to patients with skin involvement, patients with lSSc had more frequently ACA and anti-Th/To and less frequently anti-topo I and anti-RNA polymerase III antibodies. These results are in line with findings that ACA and anti-Th/To are associated with a longer disease duration at diagnosis compared with other SSc-associated ANAs [5] . Looking at SSc organ system involvement, according to a modification of Medsger's severity scale, we found 63% of the lSSc patients to have involvement of at least one organ system, most of whom had lung disease (54%). Although it was not unexpected to document SSc organ system involvement in patients with lSSc, our study is the first to systematically assess the clinical manifestations of SSc in this subset. These data emphasize the need to early identify patients without skin disease as SSc and underscore the importance of ANA detection in the identification of this subset.
Concerning the inclusion of SSc patients in this study, we need to draw attention to the fact that we did not strictly follow the LeRoy and Medsger criteria. In line with other studies [4] , we did not make a distinction between a subjective (i.e. reported by history) and objective (i.e. direct observation of at least two phases of the Raynaud sequence, or direct measurement of cold response by means of laser Doppler US, thermography, etc.) RP, as described in the original criteria by LeRoy and Medsger [3] . Instead, we defined RP as a positive history of at least two phases of colour change [4] . Also, we would like to underline that we used the LeRoy and Medsger criteria instead of the ACR criteria to define the SSc subtypes (lSSc, lcSSc and dcSSc). This may cause bias in the interpretation of data, as not all patients with lcSSc may meet the ACR criteria [22] .
In summary, the present study demonstrates the sensitivity of a standard ANA identification algorithm in a monocentric consecutive cohort of SSc patients with and without skin involvement. In our cohort, routine ANA identification showed a good sensitivity for ACA and anti-topo I, but overall sensitivity increased substantially augmented when tests for anti-RNA polymerase III, anti-PM/Scl and anti-Th/To were included. Furthermore, we looked at the prevalence of ANAs in lSSc and found ACAs and anti-Th/ To to be significantly associated with this subset. Regarding SSc organ involvement in this subset, 63% of the patients had at least one organ involvement, most of whom had lung disease. 
